Stemline Therapeutics (STML): Reiterating Buy After Positive Preliminary Data - HC Wainwright

November 21, 2016 7:35 AM EST
Get Alerts STML Hot Sheet
Price: $11.70 -3.31%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade STML Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

H.C. Wainwright analyst, Raghuram Selvaraju, reiterated his Buy rating on shares of Stemline Therapeutics (NASDAQ: STML) after the company released positive preliminary data from SL-701 in GBM at the Society for NeuroOncology (SNO) 2016 meeting.

In Stage 2 of this study, where SL-701 is being used in combination with poly-ICLC and bevacizumab, seven responses (two complete responses and five partial responses) have been observed out of 21 evaluable subjects.

For an analyst ratings summary and ratings history on Stemline Therapeutics click here. For more ratings news on Stemline Therapeutics click here.

Shares of Stemline Therapeutics closed at $12.20 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

H.C. Wainwright

Add Your Comment